» Articles » PMID: 38071738

Echocardiographic Manifestations in End-stage Renal Disease

Overview
Journal Heart Fail Rev
Date 2023 Dec 10
PMID 38071738
Authors
Affiliations
Soon will be listed here.
Abstract

End-stage renal disease (ESRD) is a common but profound clinical condition, and it is associated with extremely increased morbidity and mortality. ESRD can represent four major echocardiographic findings-myocardial hypertrophy, heart failure, valvular calcification, and pericardial effusion. Multiple factors interplay leading to these abnormalities, including pressure/volume overload, oxidative stress, and neurohormonal imbalances. Uremic cardiomyopathy is characterized by left ventricular (LV) hypertrophy and marked diastolic dysfunction. In ESRD patients on hemodialysis, LV geometry is changeable bidirectionally between concentric and eccentric hypertrophy, depending upon changes in corporal fluid volume and arterial pressure, which eventually results in a characteristic of LV systolic dysfunction. Speckle tracking echocardiography enabling to detect subclinical disease might help prevent future advancement to heart failure. Heart valve calcification also is common in ESRD, keeping in mind which progresses faster than expected. In a modern era, pericardial effusion observed in ESRD patients tends to result from volume overload, rather than pericarditis. In this review, we introduce and discuss those four echocardiography-assessed findings of ESRD, with which known and conceivable pathophysiologies for each are incorporated.

Citing Articles

Infective Endocarditis in Patients with End-Stage Renal Disease on Dialysis: Epidemiology, Risk Factors, Diagnostic Challenges, and Management Approaches.

Issa R, Chaaban N, Salahie A, Honnekeri B, Parizher G, Xu B Healthcare (Basel). 2024; 12(16).

PMID: 39201188 PMC: 11353797. DOI: 10.3390/healthcare12161631.

References
1.
Law J, Price A, Pickup L, Radhakrishnan A, Weston C, Jones A . Clinical Potential of Targeting Fibroblast Growth Factor-23 and αKlotho in the Treatment of Uremic Cardiomyopathy. J Am Heart Assoc. 2020; 9(7):e016041. PMC: 7428638. DOI: 10.1161/JAHA.120.016041. View

2.
Mall G, Huther W, Schneider J, Lundin P, Ritz E . Diffuse intermyocardiocytic fibrosis in uraemic patients. Nephrol Dial Transplant. 1990; 5(1):39-44. DOI: 10.1093/ndt/5.1.39. View

3.
Aoki J, Ikari Y, Nakajima H, Mori M, Sugimoto T, Hatori M . Clinical and pathologic characteristics of dilated cardiomyopathy in hemodialysis patients. Kidney Int. 2004; 67(1):333-40. DOI: 10.1111/j.1523-1755.2005.00086.x. View

4.
Garikapati K, Goh D, Khanna S, Echampati K . Uraemic Cardiomyopathy: A Review of Current Literature. Clin Med Insights Cardiol. 2021; 15:1179546821998347. PMC: 7907931. DOI: 10.1177/1179546821998347. View

5.
Wang X, Shapiro J . Evolving concepts in the pathogenesis of uraemic cardiomyopathy. Nat Rev Nephrol. 2019; 15(3):159-175. DOI: 10.1038/s41581-018-0101-8. View